# Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

> **NCT01761240** · PHASE1 · COMPLETED · sponsor: **Morphotek** · enrollment: 27 (actual)

## Conditions studied

- Breast Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Carcinoma, Non-Small-Cell Lung
- Adenocarcinoma

## Interventions

- **DRUG:** MORAb-066

## Key facts

- **NCT ID:** NCT01761240
- **Lead sponsor:** Morphotek
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-19
- **Primary completion:** 2016-02-09
- **Final completion:** 2016-02-09
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01761240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01761240, "Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01761240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*